Articles

Measuring cortical mean diffusivity to assess early microstructural cortical change in presymptomatic familial Alzheimer’s disease

There is increasing interest in improving understanding of the timing and nature of early neurodegeneration in Alzheimer’s disease (AD) and developing methods to measure this in vivo. Autosomal dominant famili...

Authors: Philip S. J. Weston, Teresa Poole, Jennifer M. Nicholas, Nicolas Toussaint, Ivor J. A. Simpson, Marc Modat, Natalie S. Ryan, Yuying Liang, Martin N. Rossor, Jonathan M. Schott, Sebastien Ourselin, Hui Zhang and Nick C. Fox

Neurofilament light chain in the vitreous humor of the eye

Neurofilament light chain (NfL) is a promising biomarker of neurodegeneration in the cerebrospinal fluid and blood. This study investigated the presence of NfL in the vitreous humor and its associations with a...

Authors: Manju L. Subramanian, Viha Vig, Jaeyoon Chung, Marissa G. Fiorello, Weiming Xia, Henrik Zetterberg, Kaj Blennow, Madeleine Zetterberg, Farah Shareef, Nicole H. Siegel, Steven Ness, Gyungah R. Jun and Thor D. Stein

A phase II randomized trial of sodium oligomannate in Alzheimer’s dementia

Sodium oligomannate (GV-971), a marine-derived oligosaccharide, is a novel agent that may improve cognition in AD patients.

Authors: Tao Wang, Weihong Kuang, Wei Chen, Wenwei Xu, Liming Zhang, Yingjie Li, Hailin Li, Ying Peng, Yangmei Chen, Baojun Wang, Jinsong Xiao, Honghua Li, Chuanzhu Yan, Yifeng Du, Mouni Tang, Zhiyi He…

Mesenchymal stem cell-derived exosome: a promising alternative in the therapy of Alzheimer’s disease

Alzheimer’s disease (AD) has been a devastating public health with the development of global aging. Approaches for reducing the current AD epidemic are becoming a primary focus of human healthcare due to the l...

Authors: Mengtian Guo, Zhenyu Yin, Fanglian Chen and Ping Lei

Amyloid-β_1–43 cerebrospinal fluid levels and the interpretation of APP, PSEN1 and PSEN2 mutations

Alzheimer’s disease (AD) mutations in amyloid precursor protein (APP) and presenilins (PSENs) could potentially lead to the production of longer amyloidogenic Aβ peptides. Amongst these, Aβ_1–43 is more prone to a...

Authors: Federica Perrone, Maria Bjerke, Elisabeth Hens, Anne Sieben, Maarten Timmers, Arne De Roeck, Rik Vandenberghe, Kristel Sleegers, Jean-Jacques Martin, Peter P. De Deyn, Sebastiaan Engelborghs, Julie van der Zee, Christine Van Broeckhoven and Rita Cacace

Subjective cognitive decline, anxiety symptoms, and the risk of mild cognitive impairment and dementia

Subjective cognitive decline (SCD) and anxiety symptoms both predict neurocognitive disorders, but the two correlate strongly with each other. It is unclear whether they reflect two independent disease process...

Authors: Tau Ming Liew

Association of carotid and intracranial stenosis with Alzheimer’s disease biomarkers

To clarify whether atherosclerosis of the carotid and intracranial arteries is related to Alzheimer’s disease (AD) pathology in vivo, we investigated the associations of carotid and intracranial artery stenosi...

Authors: Koung Mi Kang, Min Soo Byun, Jun Ho Lee, Dahyun Yi, Hye Jeong Choi, Eunjung Lee, Younghwa Lee, Jun-Young Lee, Yu Kyeong Kim, Bo Kyung Sohn, Chul-Ho Sohn and Dong Young Lee

T2 heterogeneity: a novel marker of microstructural integrity associated with cognitive decline in people with mild cognitive impairment

Early Alzheimer’s disease (AD) diagnosis is vital for development of disease-modifying therapies. Prior to significant brain tissue atrophy, several microstructural changes take place as a result of Alzheimer’...

Authors: Alfie R. Wearn, Volkan Nurdal, Esther Saunders-Jennings, Michael J. Knight, Hanna K. Isotalus, Serena Dillon, Demitra Tsivos, Risto A. Kauppinen and Elizabeth J. Coulthard

The Latin American Spanish version of the Face-Name Associative Memory Exam is sensitive to cognitive and pathological changes in preclinical autosomal dominant Alzheimer’s disease

To determine whether performance on the Latin American Spanish version of the Face-Name Associative Memory Exam (LAS-FNAME) can differentiate between cognitively intact carriers of an autosomal dominant Alzhei...

Authors: Clara Vila-Castelar, Nathalia Muñoz, Kathryn V. Papp, Rebecca E. Amariglio, Ana Baena, Edmarie Guzmán-Vélez, Yamile Bocanegra, Justin S. Sanchez, Eric M. Reiman, Keith A. Johnson, Reisa A. Sperling, Francisco Lopera, Dorene M. Rentz and Yakeel T. Quiroz

Analysis of brain region-specific co-expression networks reveals clustering of established and novel genes associated with Alzheimer disease

Identifying and understanding the functional role of genetic risk factors for Alzheimer disease (AD) has been complicated by the variability of genetic influences across brain regions and confounding with age-...

Authors: Daniel Lancour, Josée Dupuis, Richard Mayeux, Jonathan L. Haines, Margaret A. Pericak-Vance, Gerard C. Schellenberg, Mark Crovella, Lindsay A. Farrer and Simon Kasif

Prenatal to early postnatal neurotrophic treatment prevents Alzheimer-like behavior and pathology in mice

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder of middle-aged to old individuals. The pathophysiological process of AD is believed to begin many years before the emergence of clinical sym...

Authors: Wei Wei, Yifan Wang, Yinghua Liu, Chun-Ling Dai, Yunn-Chyn Tung, Fei Liu and Khalid Iqbal

Effects of long-term sleep disruption on cognitive function and brain amyloid-β burden: a case-control study

Recent evidence indicates that disrupted sleep could contribute to the development of Alzheimer’s disease by influencing the production and/or clearance of the amyloid-β protein. We set up a case-control study...

Authors: Jana Thomas, Sharon J. Ooms, Lara J. Mentink, Jan Booij, Marcel G. M. Olde Rikkert, Sebastiaan Overeem, Roy P. C. Kessels and Jurgen A. H. R. Claassen

The two faces of synaptic failure in App^NL-G-F knock-in mice

Intensive basic and preclinical research into Alzheimer’s disease (AD) has yielded important new findings, but they could not yet been translated into effective therapies. One of the reasons is the lack of ani...

Authors: Amira Latif-Hernandez, Victor Sabanov, Tariq Ahmed, Katleen Craessaerts, Takashi Saito, Takaomi Saido and Detlef Balschun

Visual short-term memory relates to tau and amyloid burdens in preclinical autosomal dominant Alzheimer’s disease

Over the past decade, visual short-term memory (VSTM) binding tests have been shown to be one of the most sensitive behavioral indicators of Alzheimer’s disease (AD), especially when they require the binding o...

Authors: Daniel J. Norton, Mario A. Parra, Reisa A. Sperling, Ana Baena, Edmarie Guzman-Velez, David S. Jin, Nicholas Andrea, Juna Khang, Aaron Schultz, Dorene M. Rentz, Enmanuelle Pardilla-Delgado, Joshua Fuller, Keith Johnson, Eric M. Reiman, Francisco Lopera and Yakeel T. Quiroz

Repurposed agents in the Alzheimer’s disease drug development pipeline

Treatments are needed to address the growing prevalence of Alzheimer’s disease (AD). Clinical trials have failed to produce any AD drugs for Food and Drug Administration (FDA) approval since 2003, and the phar...

Authors: Justin Bauzon, Garam Lee and Jeffrey Cummings

Normalization of CSF pTau measurement by Aβ₄₀ improves its performance as a biomarker of Alzheimer’s disease

Alzheimer’s disease (AD)-related tauopathy can be measured with CSF phosphorylated tau (pTau) and tau PET. We aim to investigate the associations between these measurements and their relative ability to predic...

Authors: Tengfei Guo, Deniz Korman, Renaud La Joie, Leslie M. Shaw, John Q. Trojanowski, William J. Jagust and Susan M. Landau

Amyloid precursor protein glycosylation is altered in the brain of patients with Alzheimer’s disease

The amyloid precursor protein (APP) is a transmembrane glycoprotein that undergoes alternative proteolytic processing. Its processing through the amyloidogenic pathway originates a large sAPPβ ectodomain fragm...

Authors: Claudia P. Boix, Inmaculada Lopez-Font, Inmaculada Cuchillo-Ibañez and Javier Sáez-Valero

Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval

The body of evidence suggesting a causative, initiating role of beta amyloid (Aβ) in the pathogenesis of Alzheimer’s disease (AD) is substantial. Yet, only a few anti-amyloid agents have shown meaningful effic...

Authors: Martin Tolar, Susan Abushakra, John A. Hey, Anton Porsteinsson and Marwan Sabbagh

Estimating the potential for dementia prevention through modifiable risk factors elimination in the real-world setting: a population-based study

Preventing dementia onset is one of the global public health priorities: around 35% of dementia cases could be attributable to modifiable risk factors. These estimates relied on secondary data and did not cons...

Authors: Elena Rolandi, Daniele Zaccaria, Roberta Vaccaro, Simona Abbondanza, Laura Pettinato, Annalisa Davin and Antonio Guaita

Neurodegenerative changes in early- and late-onset cognitive impairment with and without brain amyloidosis

A substantial number of patients clinically diagnosed with Alzheimer’s disease do not harbor amyloid pathology. We analyzed the presence and extent of tau deposition and neurodegeneration in amyloid-positive (...

Authors: Eddie C. Stage Jr, Diana Svaldi, Meredith Phillips, Victor Hugo Canela, Tugce Duran, Naira Goukasian, Shannon L. Risacher, Andrew J. Saykin and Liana G. Apostolova

Association of glial and neuronal degeneration markers with Alzheimer’s disease cerebrospinal fluid profile and cognitive functions

Neuroinflammation has gained increasing attention as a potential contributing factor in the onset and progression of Alzheimer’s disease (AD). The objective of this study was to examine the association of sele...

Authors: Unnur D. Teitsdottir, Maria K. Jonsdottir, Sigrun H. Lund, Taher Darreh-Shori, Jon Snaedal and Petur H. Petersen

The contribution of vascular risk factors in neurodegenerative disorders: from mild cognitive impairment to Alzheimer’s disease

Optimization of vascular risk factor control is emerging as an alternative approach to improve cognitive outcomes in Alzheimer’s disease, although its efficacy is still under debate. We aimed to investigate th...

Authors: Yu-Wen Cheng, Ming-Jang Chiu, Ya-Fang Chen, Ting-Wen Cheng, Ya-Mei Lai and Ta-Fu Chen

Assessing what matters most to patients with or at risk for Alzheimer’s and care partners: a qualitative study evaluating symptoms, impacts, and outcomes

The What Matters Most (WMM) study was initiated to evaluate symptoms, AD-related impacts, treatment-related needs, preferences, and priorities among individuals with or at risk for Alzheimer’s disease (AD) and...

Authors: Dana B. DiBenedetti, Christina Slota, Samantha L. Wronski, George Vradenburg, Meryl Comer, Leigh F. Callahan, John Winfield, Ivana Rubino, Holly B. Krasa, Ann Hartry, Dan Wieberg, Ian N. Kremer, Debra Lappin, Allison D. Martin, Terry Frangiosa, Virginia Biggar…

Intracranial alternating current stimulation facilitates neurogenesis in a mouse model of Alzheimer’s disease

Neurogenesis is significantly impaired in the brains of both human patients and experimental animal models of Alzheimer’s disease (AD). Although deep brain stimulation promotes neurogenesis, it is an invasive ...

Authors: Qian Liu, Yihang Jiao, Weijian Yang, Beiyao Gao, Daniel K. Hsu, Jan Nolta, Michael Russell, Bruce Lyeth, Theodore P. Zanto and Min Zhao

CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer’s disease

The presynaptic protein neuregulin1 (NRG1) is cleaved by beta-site APP cleaving enzyme 1 (BACE1) in a similar way as amyloid precursor protein (APP) NRG1 can activate post-synaptic receptor tyrosine-protein ki...

Authors: François Mouton-Liger, Julien Dumurgier, Emmanuel Cognat, Claire Hourregue, Henrik Zetterberg, Hugo Vanderstichele, Eugeen Vanmechelen, Elodie Bouaziz-Amar, Kaj Blennow, Jacques Hugon and Claire Paquet

Identification of potential blood biomarkers for early diagnosis of Alzheimer’s disease through RNA sequencing analysis

With demographic shifts toward older populations, the number of people with dementia is steadily increasing. Alzheimer’s disease (AD) is the most common cause of dementia, and no curative treatment is availabl...

Authors: Daichi Shigemizu, Taiki Mori, Shintaro Akiyama, Sayuri Higaki, Hiroshi Watanabe, Takashi Sakurai, Shumpei Niida and Kouichi Ozaki

The role of interleukin-33 in patients with mild cognitive impairment and Alzheimer’s disease

The neuroprotective role of interleukin (IL)-33 is supported by numerous preclinical studies, but it remains uninvestigated in clinical studies of Alzheimer’s disease (AD). We aimed to examine the association ...

Authors: Chih-Sung Liang, Kuan-Pin Su, Chia-Lin Tsai, Jiunn-Tay Lee, Che-Sheng Chu, Ta-Chuan Yeh, Ming-Wei Su, Guan-Yu Lin, Yu-Kai Lin, Hsuan-Te Chu, Chia-Kuang Tsai and Fu-Chi Yang

Cardiovascular risk factors indirectly affect acute post-stroke cognition through stroke severity and prior cognitive impairment: a moderated mediation analysis

Cognitive impairment is an important consequence of stroke and transient ischaemic attack, but its determinants are not fully understood. Simple univariable or multivariable models have not shown clinical util...

Authors: Bogna A. Drozdowska, Emma Elliott, Martin Taylor-Rowan, Robert C. Shaw, Gillian Cuthbertson, Peter Langhorne and Terence J. Quinn

Longitudinal changes in EEG power, sleep cycles and behaviour in a tau model of neurodegeneration

Disturbed sleep is associated with cognitive decline in neurodegenerative diseases such as Alzheimer’s disease (AD) and frontotemporal dementia (FTD). The progressive sequence of how neurodegeneration affects ...

Authors: C. M. Holton, N. Hanley, E. Shanks, P. Oxley, A. McCarthy, B. J. Eastwood, T. K. Murray, A. Nickerson and K. A. Wafford

CSF total tau/α-synuclein ratio improved the diagnostic performance for Alzheimer’s disease as an indicator of tau phosphorylation

Recently, several studies suggested potential involvements of α-synuclein in Alzheimer’s disease (AD) pathophysiology. Higher concentrations of α-synuclein were reported in cerebrospinal fluid (CSF) of AD pati...

Authors: Kyu Hwan Shim, Min Ju Kang, Jee Won Suh, Jung-Min Pyun, Nayoung Ryoo, Young Ho Park, Young Chul Youn, Jae-Won Jang, Jee Hyang Jeong, Kyung Won Park, Seong Hye Choi, Kyoungho Suk, Ho-Won Lee, Pan-Woo Ko, Chan-Nyoung Lee, Tae-Sung Lim…

Quantitative EEG as a biomarker in mild cognitive impairment with Lewy bodies

To investigate using quantitative EEG the (1) differences between patients with mild cognitive impairment with Lewy bodies (MCI-LB) and MCI with Alzheimer’s disease (MCI-AD) and (2) its utility as a potential ...

Authors: Julia Schumacher, John-Paul Taylor, Calum A. Hamilton, Michael Firbank, Ruth A. Cromarty, Paul C. Donaghy, Gemma Roberts, Louise Allan, Jim Lloyd, Rory Durcan, Nicola Barnett, John T. O’Brien and Alan J. Thomas

One third of dementia cases can be prevented within the next 25 years by tackling risk factors. The case “for” and “against”

Recently, it has been suggested that up to a third of the dementia cases might be preventable. While prevention is always better than cure, this is particularly important in the field of dementia, as current i...

Authors: Manuel Montero-Odasso, Zahinoor Ismail and Gill Livingston

Cathepsin D regulates cerebral Aβ42/40 ratios via differential degradation of Aβ42 and Aβ40

Cathepsin D (CatD) is a lysosomal protease that degrades both the amyloid β-protein (Aβ) and the microtubule-associated protein, tau, and has been genetically linked to late-onset Alzheimer disease (AD). Here,...

Authors: Caitlin N. Suire, Samer O. Abdul-Hay, Tomoko Sahara, Dongcheul Kang, Monica K. Brizuela, Paul Saftig, Dennis W. Dickson, Terrone L. Rosenberry and Malcolm A. Leissring

The insula, a grey matter of tastes: a volumetric MRI study in dementia with Lewy bodies

Despite the growing number of discoveries during the past decades about its functions, the insula remains a mysterious ‘island’. In addition to its involvement in basic functions such as gustation and interoce...

Authors: Nathalie Philippi, Vincent Noblet, Malik Hamdaoui, David Soulier, Anne Botzung, Emmanuelle Ehrhard, Benjamin Cretin and Frédéric Blanc

Community memory screening as a strategy for recruiting older adults into Alzheimer’s disease research

Growing awareness of Alzheimer’s disease (AD) has prompted a demand for quick and effective ways to screen for memory loss and cognitive decline in large numbers of individuals in the community. Periodic Memor...

Authors: Guerry M. Peavy, Cecily W. Jenkins, Emily A. Little, Christina Gigliotti, Amanda Calcetas, Steven D. Edland, James B. Brewer, Douglas Galasko and David P. Salmon

Imaging the aging brain: study design and baseline findings of the SENIOR cohort

Current demographic trends point towards an aging society entailing increasing occurrence and burden of neurodegenerative diseases. In this context, understanding physiological aging and its turning point into...

Authors: Alexa Haeger, Jean-François Mangin, Alexandre Vignaud, Cyril Poupon, Antoine Grigis, Fawzi Boumezbeur, Vincent Frouin, Jean-Robert Deverre, Marie Sarazin, Lucie Hertz-Pannier and Michel Bottlaender

The short-term effects of sedentary behaviour on cerebral hemodynamics and cognitive performance in older adults: a cross-over design on the potential impact of mental and/or physical activity

Sedentary behaviour might be a potential risk factor for cognitive decline. However, the short-term effects of sedentary behaviour on (cerebro) vascular and cognitive performance in older people are unknown.

Authors: Carlijn M. Maasakkers, René J. F. Melis, Roy P. C. Kessels, Paul A. Gardiner, Marcel G. M. Olde Rikkert, Dick H. J. Thijssen and Jurgen A. H. R. Claassen

Diverse proteins aggregate in mild cognitive impairment and Alzheimer’s disease brain

All cells accumulate insoluble protein aggregates throughout their lifespan. While many studies have characterized the canonical disease-associated protein aggregates, such as those associated with amyloid pla...

Authors: Devin Kepchia, Ling Huang, Richard Dargusch, Robert A. Rissman, Maxim N. Shokhirev, Wolfgang Fischer and David Schubert

The dynamics of biomarkers across the clinical spectrum of Alzheimer’s disease

Quantifying changes in the levels of biological and cognitive markers prior to the clinical presentation of Alzheimer’s disease (AD) will provide a template for understanding the underlying aetiology of the cl...

Authors: Christoforos Hadjichrysanthou, Stephanie Evans, Sumali Bajaj, Loizos C. Siakallis, Kevin McRae-McKee, Frank de Wolf and Roy M. Anderson

Optical coherence tomography angiography as a potential screening tool for cerebral small vessel diseases

The retina and the brain share anatomic, embryologic, and physiologic characteristics. Therefore, retinal imaging in patients with brain disorders has been of significant interest. Using optical coherence tomo...

Authors: Ju-Yeun Lee, Jun Pyo Kim, Hyemin Jang, Jaeho Kim, Sung Hoon Kang, Ji Sun Kim, Jongmin Lee, Young Hee Jung, Duk L. Na, Sang Won Seo, Sei Yeul Oh and Hee Jin Kim

Plasma transferrin and hemopexin are associated with altered Aβ uptake and cognitive decline in Alzheimer’s disease pathology

Heme and iron homeostasis is perturbed in Alzheimer’s disease (AD); therefore, the aim of the study was to examine the levels and association of heme with iron-binding plasma proteins in cognitively normal (CN...

Authors: Azhaar Ashraf, Nicholas J. Ashton, Pratishtha Chatterjee, Kathryn Goozee, Kaikai Shen, Jurgen Fripp, David Ames, Christopher Rowe, Colin L. Masters, Victor Villemagne, Abdul Hye, Ralph N. Martins and Po-Wah So

Correction to: Relevance of biomarkers across different neurodegenerative diseases

An amendment to this paper has been published and can be accessed via the original article.

Authors: Alexander J. Ehrenberg, Ayesha Khatun, Emma Coomans, Matthew J. Betts, Federica Capraro, Elisabeth H. Thijssen, Konstantin Senkevich, Tehmina Bharucha, Mehrsa Jafarpour, Peter N. E. Young, William Jagust, Stephen F. Carter, Tammaryn Lashley, Lea T. Grinberg, Joana B. Pereira, Niklas Mattsson-Carlgren…

Young blood plasma reduces Alzheimer’s disease-like brain pathologies and ameliorates cognitive impairment in 3×Tg-AD mice

Recent studies indicated that circulatory factors in blood plasma from young animals can reactivate neurogenesis, restore synaptic plasticity, and improve cognitive function in aged animals. Here, we investiga...

Authors: Ying Zhao, Ran Qian, Jin Zhang, Fei Liu, Khalid Iqbal, Chun-Ling Dai and Cheng-Xin Gong

Immediate and long-term consequences of COVID-19 infections for the development of neurological disease

Increasing evidence suggests that infection with Sars-CoV-2 causes neurological deficits in a substantial proportion of affected patients. While these symptoms arise acutely during the course of infection, les...

Authors: Michael T. Heneka, Douglas Golenbock, Eicke Latz, Dave Morgan and Robert Brown

Reproducibility of EEG functional connectivity in Alzheimer’s disease

Although numerous electroencephalogram (EEG) studies have described differences in functional connectivity in Alzheimer’s disease (AD) compared to healthy subjects, there is no general consensus on the methodo...

Authors: Casper T. Briels, Deborah N. Schoonhoven, Cornelis J. Stam, Hanneke de Waal, Philip Scheltens and Alida A. Gouw

A decade of Alzheimer’s Research & Therapy: reflections on the past, present, and future

Authors: Douglas Galasko and Philip Scheltens

The Alzheimer’s Prevention Initiative Composite Cognitive Test: a practical measure for tracking cognitive decline in preclinical Alzheimer’s disease

There is growing interest in identifying sensitive composite cognitive tests to serve as primary endpoints in preclinical Alzheimer’s disease (AD) treatment trials. We reported previously a composite cognitive...

Authors: Jessica B. Langbaum, Noel N. Ellison, Angelika Caputo, Ronald G. Thomas, Carolyn Langlois, Marie-Emmanuelle Riviere, Ana Graf, Cristina Lopez Lopez, Eric M. Reiman, Pierre N. Tariot and Suzanne B. Hendrix

APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer’s disease

Aggregation of amyloid β into plaques in the brain is one of the earliest pathological events in Alzheimer’s disease (AD). The exact pathophysiology leading to dementia is still uncertain, but the apolipoprote...

Authors: Elles Konijnenberg, Betty M. Tijms, Johan Gobom, Valerija Dobricic, Isabelle Bos, Stephanie Vos, Magda Tsolaki, Frans Verhey, Julius Popp, Pablo Martinez-Lage, Rik Vandenberghe, Alberto Lleó, Lutz Frölich, Simon Lovestone, Johannes Streffer, Lars Bertram…

Testing whether the progression of Alzheimer’s disease changes with the year of publication, additional design, and geographical area: a modeling analysis of literature aggregate data

Our objectives were to develop a disease progression model for cognitive decline in Alzheimer’s disease (AD) and to determine whether disease progression of AD is related to the year of publication, add-on tri...

Authors: Ningyuan Zhang, Xijun Zheng, Hongxia Liu, Qingshan Zheng and Lujin Li

Partial reduction of amyloid β production by β-secretase inhibitors does not decrease synaptic transmission

Alzheimer’s disease (AD) is the most common form of age-related neurodegenerative diseases. Cerebral deposition of Aβ peptides, especially Aβ42, is considered the major neuropathological hallmark of AD and the...

Authors: Tugce Munise Satir, Lotta Agholme, Anna Karlsson, Mattias Karlsson, Paul Karila, Sebastian Illes, Petra Bergström and Henrik Zetterberg